<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510610</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-056</org_study_id>
    <nct_id>NCT04510610</nct_id>
  </id_info>
  <brief_title>Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma</brief_title>
  <official_title>An Open-label, Multicenter, phase2/3 Study of Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 2/3ï¼Œmulticenter and single-arm clinical trial of Camrelizumab&#xD;
      plus decitabine for Anti-PD-1 treatment-naive patients with relapsed or refractory Hodgkin&#xD;
      Lymphoma. The primary objective of this study is to evaluate the long-term response duration&#xD;
      with Camrelizumab plus decitabine in relapsed or refractory Hodgkin Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of response</measure>
    <time_frame>5 years</time_frame>
    <description>Time measured from the day of first documented PR or CR to the date of first documented progression, or death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time measured from the day of treatment to the date of first documented progression, or death from any cause</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab plus decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine 10 mg/day, days 1-5; Camrelizumab 200 mg, day 8, every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab and Decitabine</intervention_name>
    <description>Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.</description>
    <arm_group_label>Camrelizumab plus decitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1 Subjects must have histological confirmation of relapsed or refractory Hodgkin&#xD;
             lymphoma (HL).&#xD;
&#xD;
          -  2 12 to 75 years of age.&#xD;
&#xD;
          -  3 ECOG performance of less than 2.&#xD;
&#xD;
          -  4 Life expectancy of at least 3 months.&#xD;
&#xD;
          -  5 Subjects with lymphoma must have at least one measureable lesion &gt;1 cm as defined by&#xD;
             lymphoma response criteria.&#xD;
&#xD;
          -  6 Subjects must have received at least two lines of prior regimens without Anti-PD-1&#xD;
             antibody treatment history, and must be off therapy for at least 4 weeks prior to Day&#xD;
             1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which&#xD;
             must be more than 3 months.&#xD;
&#xD;
          -  7 Subjects must have adequate marrow, live, renal and heart functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1 Subjects with any autoimmune disease or history of syndrome that requires&#xD;
             corticosteroids or immunosuppressive medications.&#xD;
&#xD;
          -  2 Serious uncontrolled medical disorders or active infections, pulmonary infection&#xD;
             especially.&#xD;
&#xD;
          -  3 Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1&#xD;
             month .&#xD;
&#xD;
          -  4 Prior organ allograft.&#xD;
&#xD;
          -  5 Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  6 Women with a positive pregnancy test on enrollment or prior to nvestigational&#xD;
             product administration.&#xD;
&#xD;
          -  7 Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weidong Han, M.D.</last_name>
    <phone>+861055499341</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han</last_name>
      <phone>86-10-13651392893</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

